August 2026: TGA Suspends Supply of Corpuls 3 and Corpuls 3T Defibrillators in Australia Until 25 November 2026

Event Summary

On 12 August 2026, the Australian Therapeutic Goods Administration (TGA) published a media release, "Safety of Medical Devices," confirming that it had taken suspension action against the Corpuls 3 and Corpuls 3T defibrillators. During the suspension period, no new supply of the affected products is permitted; devices already placed into use are not subject to restrictions on use.

Regulatory Action Record

According to the regulatory action record published by the TGA, the action concerns the entry "Physiologic-monitoring defibrillation system" (ARTG entry number 17882). The action type is "Suspension from the ARTG under paragraph 41GA(1)(b) of the Therapeutic Goods Act 1989." The action took effect on 25 August 2026 and expires on 25 November 2026, giving a suspension period of three months.

Grounds and Legal Basis

The TGA stated that the suspension was taken while the investigation into reports of "unexpected shutdown and restart during use" remains ongoing. The legal basis cited in the action record is paragraph 41GA(1)(b), which is expressed as: it is likely that there are grounds for cancelling the entry for the device.

The TGA also emphasised that a suspension does not amount to a finding that the devices are unsafe, and explicitly stated that no recall has been issued for these devices. The TGA further noted that regulatory action may be taken for safety, quality or performance reasons, but that regulatory action does not always mean a product must be withdrawn from the market, nor does it mean that the product is unsafe.

What Remains Permitted and What Is No Longer Allowed During the Suspension

During the suspension period, Corpuls 3 and Corpuls 3T devices already in use in ambulances and healthcare facilities may continue to be used and maintained. What is no longer permitted is new supply — that is, the sponsor and manufacturer may not place new devices on the market during the suspension period.

The TGA stated that it has provided information about the suspension to healthcare facilities and authorities, and has required the sponsor and manufacturer to submit additional documentary evidence to further demonstrate the effectiveness of corrective actions (including software-related restart issues) and the adequacy of their systems and processes for identifying, investigating and responding to device problems and non-conformities.

Parties and Product Scope

The Australian sponsor of the products concerned is Device Technologies Australia Pty Ltd (DTA), and the manufacturer is Corpuls. The TGA stated that both parties have agreed to provide additional information to inform the public about the safety of the Corpuls 3 and 3T.

It should be noted that this suspension applies to the Corpuls 3 and Corpuls 3T as listed under a specific ARTG entry (number 17882), and not to all defibrillation equipment on the Australian market.

Timeline and Next Steps

The TGA media release was published on 12 August 2026; the suspension took effect on 25 August 2026 and expires on 25 November 2026. The TGA stated that if the relevant safety, quality or performance issues can be addressed during the suspension period, the entry may be reinstated through the applicable process once the suspension expires; otherwise, cancellation proceedings for the entry may follow. The regulatory action record also states that the grounds are that "it is likely that there are grounds for cancelling the device's entry."

The TGA stated that it will publish information about regulatory activity as soon as practicable, so that affected users, healthcare facilities and other interested parties can assess their own situations and put in place risk mitigation or alternative arrangements.

Sources and Applicability Note

Sources: Therapeutic Goods Administration (TGA), media release "Safety of Medical Devices," published 12 August 2026: https://www.tga.gov.au/news/media-releases/safety-medical-devices

TGA regulatory action record: Physiologic-monitoring defibrillation system (17882): Corpuls 3 and Corpuls 3T (Suspension from the ARTG under paragraph 41GA(1)(b) of the Act), action effective 25 August 2026, expiry 25 November 2026: https://www.tga.gov.au/resources/cancellations-suspensions/physiologic-monitoring-defibrillation-system-17882-corpuls-3-and-corpuls-3t-suspension-artg-under-paragraph-41ga1b-act

Verification scope and access date: This verification accessed the above TGA media release page and the TGA regulatory action record page on 30 September 2026 (Beijing time). The dates, paragraph numbers, product names and entity names in this article follow the original text of the official TGA pages.

Applicability note: This article is an interpretation of publicly available TGA regulatory information and does not constitute a conclusion or commitment regarding any specific product, company or registration application. Suspension and recall are regulatory actions of a different nature; specific handling should be based on the original TGA text and subsequent updates, and the relevant information may change as official updates are issued.

AIMEILI Regulatory Interpretation

The TGA action is best understood as a pre-cancellation suspension rather than a product removal: it stops new market supply for a defined three-month window while the sponsor and manufacturer close out the evidence gaps identified by the regulator. The recorded statutory ground — it is likely that there are grounds for cancelling the entry — indicates that cancellation remains an available outcome if the issues are not resolved before 25 November 2026.

• Suspension is not a recall, but it is a serious escalation. The TGA has not required devices in the field to be retrieved, which implies that continued clinical use, supported by maintenance and monitoring, has been assessed as acceptable in risk terms. At the same time, a suspension based on a likely cancellation ground sits at the higher end of the post-market action spectrum and is usually preceded by unresolved or insufficiently substantiated corrective actions.
• The "unexpected shutdown and restart" signal points to software and system-level controls. Where restart phenomena are reported, regulators typically expect root cause analysis covering software design, verification and validation, risk management (including risk control effectiveness and residual risk evaluation), usability and field data trending — not only a firmware fix. Evidence of corrective action effectiveness over time, rather than a one-off patch, is normally the decisive element.
• The evidentiary request extends beyond the product to the QMS. The TGA has asked for evidence that the systems and processes for identifying, investigating and responding to device problems and non-conformities are adequate. In practice this reads as a documentation-based review of complaint handling, adverse event reporting, non-conformity and CAPA processes, and the associated records, so the response package should be built as a coherent, traceable file rather than as separate answers.
• Scope discipline matters. The action is tied to a single ARTG entry (17882). Communications, field actions and regulatory responses should therefore be scoped to the affected configurations and software versions, with clear traceability by UDI, model and version, to avoid implying that all defibrillation equipment in Australia is affected.
• The three-month window is a hard deadline. Key dates are the effective date of 25 August 2026 and the expiry date of 25 November 2026. Reinstatement, extension or progression to cancellation will generally depend on whether the TGA is satisfied with the evidence submitted before expiry.
• Cross-jurisdictional read-across is likely. Comparable post-market signals in other markets can trigger information requests from other regulators and notified bodies and can affect technical documentation and periodic safety reporting. Consistency of root cause conclusions and corrective action status across jurisdictions is important, and discrepancies are a common source of follow-up questions.

Business Impact

For manufacturers, sponsors and distributors, the immediate commercial effect is a halt to new Australian supply for up to three months, with continued obligations for devices already in service. The operational effect is a concentrated, evidence-intensive regulatory workstream with a fixed completion date.

• Supply continuity and commercial exposure. New supply is prohibited during the suspension period, which can affect inventory deployment, tender and contract fulfilment, hospital procurement timelines and revenue recognition in Australia. Distributors should confirm with the TGA what activities fall within the scope of "new supply" — for example replacement units, accessories, spare parts and service exchange units — and should plan stock allocation and customer communication accordingly.
• Installed base and service obligations. Devices already in use may continue to be used and maintained, so service, maintenance and clinical support arrangements should remain in place, with particular attention to user instructions and monitoring for unexpected shutdown and restart in the field.
• Evidence package preparation. Priority workstreams typically include root cause analysis of the restart reports; software verification and validation records; risk management documentation demonstrating that risk controls are effective and residual risk is acceptable; complaint and adverse event trending; and CAPA effectiveness checks with objective evidence.
• QMS demonstration. The TGA request for evidence on problem and non-conformity handling means the underlying processes, procedures and records should be reviewable and internally consistent. Gaps between procedure and practice will be visible in a documentation-based review.
• Communication and stakeholder management. Healthcare facilities and authorities have already been notified by the TGA. Aligning the sponsor's and manufacturer's communications with the regulatory framing — suspension, not recall — helps avoid unnecessary withdrawal of devices from clinical use while still supporting appropriate risk mitigation.
• Planning horizon. The practical decision point is 25 November 2026. Teams should prepare for three scenarios: reinstatement of supply, an extension or further regulatory action, or progression toward cancellation, each of which carries different implications for supply commitments, registration strategy and customer relationships.